AMR.Solutions

Powered by CARB-X: Portfolio expansion announced today!

Picture

​Dear All: CARB-X has today announced funding of 7 more companies, bringing the total funded portfolio to 17 potential new therapies (or preventatives) and 1 novel point-of-care diagnostic (see graphic above). Befitting the international nature of those of you who read my occasional notes (see map just below), there are now funded companies in 6 countries (US, UK, France, Switzerland, Ireland, and India). 

Picture

Above: Locations of recent readers of these newsletters. Darker = more readers
​You can read more in the press release (and don’t miss the two interactive & clickable portfolio tables), but I think it is particularly exciting that the 7 new projects include five potential new class antibiotics for Gram-negative bacteria. These will take a long time to mature and only a few will ultimately succeed, but the therapeutic part of the portfolio now contains 10 projects that pursue a novel target and 8 that are potential novel class small molecules.  

All best wishes, –jr

PS: For those of you who miss the broadcast or don’t have a local PBS station, the FRONTLINE episode of Hunting the Nightmare Bacteria will be available for streaming at http://www.pbs.org/wgbh/frontline/ beginning sometime in the next 24h.

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html

Upcoming meetings of interest to the AMR community:

Menu-01-01

Share

More Newsletters

EPA (part 2, streptomycin!) / $104m ARPA-H AMR project

Dear All (OK, so now it’s 5 newsletters in as many days … exciting times … can’t keep up!), Two follow-up items today. First, yesterday’s newsletter about EPA’s concept note regarding AMR risks of pesticides prompted one of your fellow readers to remind me about this lawsuit filed with the U.S. Court of Appeals, Ninth Circuit: Case

BARDA Medical Countermeasures BAA: Substantial updates

Dear All (and yes, back-to-back newsletters … lots of action this week!): BARDA have today released a new version of their long-running BAA (Broad Agency Announcement, formerly BAA-18-100-SOL-00003) that seeks medical countermeasures (MCMs) for chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. The new BAA is BAA-23-100-SOL-00004 and has been completely reorganized and

Appropriate duration of antimicrobial dosing in food animal care

Dear All,  I’ve watched with interest the way that FDA’s CVM (Center for Veterinary Medicine) has been working steadily with the veterinary community as a whole to reduce antibiotic resistance pressure by improving the way antibiotics are used in animal care. The titles of these prior newsletters give you a feel for some aspects of

More Newsletters
Subscribe

AMR.Solutions

Using ideas to connect, create, and inspire

Twitter Facebook Linkedin Envelope Instagram Youtube

Supported by the Wellcome Trust

Privacy Policy

Site Map

Scroll to Top